Helix Acquisition Corp. II
| IPO Proceeds, $M | $184.00M |
|---|---|
| IPO Date | Feb 9, 2024 |
| CEO | Bihua Chen |
| Left Lead | Leerink Partners |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biotechnology sector |
| IPO Geography | US/Canada |
| Target Company | TBD |
| Deal Announced | TBD |
| Deal Size, $M | TBD |
| Deal Sector | TBD |
| Deal Geography | TBD |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | TBD |
| Price | $10.42 |
|---|---|
| Last closing price | $10.42 |
| H/L, today | $10.42 / $10.56 |
| Volume, today | 5,823 |
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on Helix Acquisition Corp. II:
- Structure and cap table
- 5 directors & officers
- 5 filings and events
- 1 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Bihua Chen | 55 | Chairperson and Chief Executive Officer |
| Caleb Tripp | 38 | Chief Financial Officer |
| Nebojsa Obradovic | 53 | Chief Legal Officer |
| John Schmid | 60 | Director |
| Mark McKenna | 44 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
| Leerink Partners | BR | 16,000,000 | units |
| 16,000,000 | units | ||
| Up-Front UW fee | 1.00 | % | |
| Deferred UW fee |
3.00 | % |
Sign in to view more advisor data.
Filings
| Jan 18, 2024 | Initial S-1 |
| Feb 2, 2024 |
Amended S-1
Sign In to view filing content. |
| Feb 9, 2024 |
PR announcing pricing of upsized $160mm IPO
Sign In to view filing content. |
| Feb 13, 2024 | 424B4 IPO Prospectus |
| Feb 14, 2024 |
8-K announcing full over-allotment exercise
Sign In to view filing content. |